Risk factor
Strong & resilient to price shocks
Profitability factor
Greatly overvalued vs peers
About
Shilpa Medicare Limited, including its various subsidiaries, manufactures and distributes a range of active pharmaceutical ingredients (APIs), intermediate compounds, and finished drug formulations. Operating across India, the United States, Europe, and other international markets, their product lineup encompasses both oncology and non-oncology APIs. The company also innovates with new drug delivery systems, biological products such as peptides, and specialized chemicals. Furthermore, Shilpa Medicare provides contract manufacturing services for diverse dosage forms, including tablets, capsules, liquid and lyophilized injectables, and sterile dry powder injectables. Beyond its pharmaceutical operations, the firm also participates in wind power generation. Founded in 1987, Shilpa Medicare Limited maintains its headquarters in Raichur, India.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB
Target Price
The average target price of SHILPAMED.NS is 508 and suggests 47.1% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendati